How patients with multiple sclerosis acquire disabilityFred Lublin, Robert A Bermel, Dieter A. Häring et al.|Brain|2022Cited by 532
TH17 cells promote CNS inflammation by sensing danger signals via MincleQuanri Zhang, Xiaoxia Li, Weiwei Liu et al.|Nature Communications|2022Cited by 34
AI-driven reclassification of multiple sclerosis progressionHabib Ganjgahi, Chris Holmes, Alan J. Thompson et al.|Nature Medicine|2025Cited by 29
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trialsTobias Derfuß, Amit Bar‐Or, Robert A Bermel et al.|Therapeutic Advances in Neurological Disorders|2024Cited by 23
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock‐Guttman, Jerry S. Wolinsky, Robert A Bermel et al.|Multiple Sclerosis Journal|2021Cited by 23